CCKBR and depressive disorder: The effectiveness of the small non-opiate scFv antibody targeting the cholecystokinin B receptor (CCK-BR) alleviation of chronic orofacial hypersensitivity is sufficient to prevent development of anxiety and depression in the chronic model.